Active Ingredient History
Rasburicase is a medication that helps to clear uric acid from the blood. It is a recombinant version of urate oxidase, an enzyme that metabolizes uric acid to allantoin. Urate oxidase is known to be present in many mammals but does not naturally occur in humans. Rasburicase is produced by a genetically modified Saccharomyces cerevisiae strain. The complementary DNA (cDNA) coding for rasburicase was cloned from a strain of Aspergillus flavus. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Hyperuricemia (approved 2002)
Burkitt Lymphoma (Phase 2)
Gout (Phase 4)
Graft vs Host Disease (Phase 1)
Healthy Volunteers (Phase 1)
Hyperuricemia (Phase 4)
Leukemia (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myeloid, Chronic-Phase (Phase 2)
Lymphoma (Phase 4)
Lymphoma, B-Cell (Phase 2/Phase 3)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Non-Hodgkin (Phase 3)
Multiple Myeloma (Phase 1)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 1)
Neoplasms (Phase 4)
Nutritional and Metabolic Diseases (Phase 2)
Tumor Lysis Syndrome (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
